Ge e a General Presentation ese tat o

February 2012

Contents
Page 1. Corporate Strategy 2. 2 FY 2011 Fi Financial P f i l Performance 3. FY 2011 Key Product Performance 4. 4 R&D U d t Update 5. Strategy update & Planning assumptions 2012+ 6. News fl 6 N flow 2011 7. AZN - Historic performance & Shareholder returns 8. Key industry 8 K i d t growth drivers th d i 9. Q4 Financial & Key Product Performance 10. Investor Relations contacts 10 I R l i 11. Appendices 3 7 15 45 81 99 101 106 124 136 139

Co po ate St ategy Corporate Strategy

Strategy

Industry outlook
Increasing and ageing populations Expanding populations in new markets Significant unmet medical need Continued scientific and technological advance

Growth Sector

Pressures on returns Leading players will continue to earn attractive returns

Strategy

Decline in R&D productivity p y Established market price pressure Patent expiries and genericisation

Increased R&D productivity opportunities Adapting sales and marketing model Further cost reduction potential Improved investment discipline

Our vision
AstraZeneca is
Focused Innovation-driven Integrated Global Biopharma
OUR VALUES

Strategy

Corporate Strategic priorities

Making the most meaningful difference to patient health through great medicines
Pipeline Deliver the business Business Shape People

Increase output Drive productivity & efficiency

Growth of current products Successfully launch the new products Drive growth in emerging markets Develop innovative p channels to meet customer needs

Implement asset strategy & LEAN Drive efficiencies in Sales & Marketing and G&A d Focus Capex on productivity improvements p

Innovation Accountability Lean & agile Value orientation

- Disease area focus - Reduce site footprint - Externalisation - Build stronger relationship l ti hi with payers

Collaboration

Manage for long term shareholder value long-term

Our values

Strategy

FY 2011 Financial 0 a ca Performance

Financial Performance

FY 2011 Summary
Financial performance
Revenue $33,591m (-2% CER) Reflects loss of nearly $2bn from generic competition & further $1bn lost to the impact from government price interventions Core EPS $7.28 (+7% CER) $7 28 Strong performance of Crestor, Symbicort, Seroquel XR

Research & Development

Further approvals and launches of Brilique/BRILINTA now approved in 64 counties and launched in 37 Nexium and Faslodex approved in Japan Announced full results from SATURN Market authorisation received in EU for KOMBOGLYZE in Q4 On 19th of Jan 2012 FDA issued a complete response letter regarding the NDA for dapagliflozin TC-5214 phase III studies, RENAISSANCE 3 & 2, did not meet their primary endpoints Announced the decision to discontinue olaparibs development in serous ovarian cancer

Shareholder returns
Dividend 2011 $2.80 (+10%) Net cash distributions to shareholders 2011 +71% to $9.4bn vs. 2010 through net share repurchases of $5.6bn & $3.8bn through the payment of the second interim dividend from 2010 and the first dividend from 2011

Other developments
Disposal of Astra Tech business to DENTSPLY for appro imatel $1.8bn in cash completed in August approximately $1 8bn A g st 2011. Net proceeds added to share repurchases

Financial Performance

Performance

Headline results FY 2011

FY 2011 $m FY 2010 $m Actual CER

Revenue Core Operating Profit Core EPS

Restructuring R t t i MedImmune/Merck amortisation Intangible Impairments Legal provisions Employee Benefits E l B fit Astra Tech sale

33,591 13,167 13 167 $7.28

($0.63) ($0 63) ($0.32) ($0.01) ($0.07) $1.08

33,269 13,603 13 603 $6.71

($0.62) ($0 62) ($0.29) ($0.29) ($0.39) $0.40 $0 40

+1% -3% +9%

-2% -4% +7%

Reported EPS

$7.33

$5.60

+31% 31%

+29% 29%

Financial Performance

Performance

Regional revenue performance FY 2011

FY 2011 $m Global Revenue US Western Europe Established RoW Emerging Markets 33,591 33 591 13,426 8,501 5,901 5 901 5,763 CER % -2% 2% -2% -11% +4% +10% CER $m -599 599 -302 -1,047 +229 +521

Financial Performance

Performance

10 10

Key brand revenue summary FY 2011

FY 2011 $m CER %

Crestor Seroquel
Seroquel IR Seroquel XR

6,622 6 622 5,828

4,338 4 338 1,490

+13% +8%
+3% +27%

Nexium Symbicort

4,429 3,148

-12% 12% +11%

Financial Performance

Performance

11 11

Core margin: FY 2011

$m Revenue Core Gross Margin Distribution Core SG&A C Core Other Income Core Pre-R&D Profit Core R&D Operating Profit 33,591 27,619 (346) (9,918) (9 918) 845 18,200 (5,033) (5 033) 13,167 CER growth -2% 0% -1% -2% 2% -8% 0% +15% -4% 82.2 1.0 29.5 29 5 2.5 54.2 15.0 15 0 39.2 +130bps 0bps -10bps 10 -20bps +100bps -220bps 220 -120bps % sales Delta vs PY CER

Financial Performance

Performance

12 12

Cash generation: FY 2011

2011 $m Opening net cash/(debt) EBITDA Movement in working capital Tax & interest paid* Other non-cash movements** 3,653 15,345 15 345 (897) (3,164) (2,080) 9,204 Tax settlements Net cash from operating activities ( , (1,383) ) 7,821 2010 $m 535 14,235 14 235 82 (2,612) (463) 11,242 ( (562) ) 10,680

Financial Performance

Performance

* Adjusted for Tax settlements, ** Including $1483 million from AstraTech disposal

13 13

Cash application: FY 2011

2011 $m Opening net cash/(debt) 3,653

Net cash from operating activities Net capex Astra Tech Disposal Proceeds Dividends/Net share buy-back Other movements Closing net cash/(debt) Gross debt Cash/Cash equivalents and STIs

7,821 (1,195) 1,772 (9,370) 168 2,849 (9,328) 12,177

Financial Performance

Performance

14 14

FY 2011 Key Product Performance

Product Performance

Crestor
FY 2011 Sales: $6,622m +13% CER
EM ROW $661m +8% EST ROW $1,662m +15% W. EUR $1,225m +5%

Global volume growth 2x statin market (12% vs 6%) Crestor US TRx +4% - Statin market +1% - Generic atorvastatin launched end November - Crestor TRx volume stable 5% Western Europe sales +5% Double-digit growth in France and Spain Established ROW sales +15% Japan accounts for half of the increase Emerging Markets sales +8% Good growth in Emerging Europe & China Generics in Brazil

6,000 5,000 , 4,000 3,000 3 000 2,000 1,000 0

FY 10 US EST ROW Product Performance FY 11

US $3,074m +16%

W EUR EM ROW
16 16

Crestor TRx volume stable post generic atorvastatin t t ti

600,000 600 000

Generic Atorvastatin November 30th

Growth vs prior year 8 weeks pre vs 8 weeks post

Pre/Post

500,000

+2% / +2%

400,000

300,000 300 000

Pre/Post
200,000

+6% / +1%

100,000

Pre/Post +4% / -10%

09/02/11 09/09/11 09/16/11 09/23/11 09/30/11 10/07/11 10/14/11 09/02/11 10/28/11 11/04/11 11/11/11 11/18/11 11/25/11 12/02/11 12/09/11 12/16/11 12/23/11 12/30/11 1/13/12 1/20/12 1/6/112 0

**

TRx

NRx

NBRx

Product Performance

* Source: IMS NPA Market Dynamics, Data Week ending 01/20/12 (TRx, NRx) ** Source: IMS NPA Market Dynamics, Data Week ending 01/13/12 (NBRx)

17 17

Crestor: STELLAR study LDL-C lowering across the dose range LDL C l i th d
LDL-C: LS mean change from baseline at week 6
0 -5 -10 -15 20 -25
10 mg

-30

-35

-40

-45

-50
20 mg

-55
40 mg

-60 CRESTOR

10 mg *** 10 mg *** 10 mg *** 20 mg *** 40 mg *** 20 mg *** 40 mg ***

20 mg ^^^ 80 mg ^^^

40 mg ^^^

80 mg

Atorvastatin

Simvastatin

Pravastatin
CRESTOR 10mg 10 (-46%)
DATA ON FILE

CRESTOR 20mg (-52%)

Product Performance

*p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

18 18

SATURN: IVUS study vs Lipitor

Hypothesis: the greater impact of Crestor on LDL-C & HDL-C will translate into a greater impact on atherosclerosis
Coronary Artery Disease Patients
N~2900 screened Hypercholesterolaemic Left main coronary artery: 50% reduction in lumen diameter Target coronary artery: <50% reduction in lumen diameter of 40 mm segment Visit: 18-75 years Week:

1300 Re-randomised Re randomised patients RSV 20 mg Crestor 40 mg (n=650)

ATV 40 mg
Pre-treatment 1 4
IVUS Lipids

atorvastatin 80 mg (n=650)

2 2
Lipids Tolerability

3 0

4 13

5 26

6 39

7 52

8 65

9 78

10 91

11 104

Tolerability

Lipids Lipids Lipids Tolerability IVUS Lipids Tolerability Tolerability Tolerability

Headlines Results:
Treatment with Crestor (rosuvastatin) or atorvastatin for two years resulted in statistically significant regression in the primary efficacy measure, change from baseline in percent atheroma volume (PAV) in a 40 mm segment of the targeted coronary artery as assessed by intravascular ultrasound (IVUS). Crestor 40mg demonstrated a numerically greater reduction versus atorvastatin 80mg, but did not reach statistical significance (-1.22% vs. -0.99%; p=0.17). For the secondary efficacy measure of normalized total atheroma volume (TAV), Crestor demonstrated a (TAV) 3 vs. -4.42 mm3; p=0.01). statistically significant reduction compared with atorvastatin (-6.39 mm Product Performance
CAD=coronary artery disease; IVUS=intravascular ultrasound Data and analyses presented by the studys academic investigators at AHA in Nov 2011 and published in NEJM the 15th of Nov. ref 10.1056/NEJMMoa1110874

19 19

Seroquel
FY 2011 Sales: $5,828m +8% CER
6,000 5,000 4,000 3,000 2,000 1,000 1 000 0
FY 10 US EST ROW Product Performance
*IMS MAT Nov 2011

Seroquel IR: $4,338m +3% Seroquel XR: $1,490m +27% Global

EM ROW $352m -1% EST ROW $317m 1% W. W EUR $1,036m +7%

Seroquel franchise value market share at 27.8%*

US Market share for Seroquel franchise was a market leading 29.8% at end of Dec Seroquel IR were $3,344m, up 8% ROW

US $4,123m +10%

Seroquel IR declined by 8% in Western Europe to $546m Seroquel franchise sales in Emerging Markets were down 1%, where a 41% increase for Seroquel XR was more than offset by declines for Seroquel IR in Brazil following loss of q g exclusivity Seroquel XR now 26% of global franchise revenue - US: 19% of franchise
20 20

FY 11 W EUR EM ROW

- ROW: 42% of franchise

Seroquel XR
FY 2011 Sales: $1,490m +27% CER Global
1,400 1,200 1,000 800 600 400 200 0
FY 10 US EST ROW Product Performance FY 11 W EUR EM ROW
21 21

EM ROW $132m +41% EST ROW $89m +34% W. W EUR $490m +30%

Seroquel XR is the fastest growing branded atypical in value globally US US sales for Seroquel XR +22% to $799 million. ROW Sales of Seroquel XR in ROW increased by 32%, accounting for 42% of franchise sales outside the US Emerging markets: Strong growth of Seroquel XR +41% Further launches in Emerging markets planned in 2012

US $779m +22%

Seroquel XR: new indications to drive growth

SCHIZOPHRENIA High dose Smaller market BIPOLAR Medium dose Medium market MDD (DEPRESSION) Low dose Large market

Average dose

400mg3

9 months1

600mg3

7-8 months1

4-8 months1

1. IMS Longitudinal patient data 2. AZ SEROQUEL Clinical Development program 3. US 2005 Patient Record Dosing Study (Gallagher Research) 4. Datamonitor

150mg2 Average treatment duration

Si e of Size Patient population

Product Performance

22 22

Symbicort
FY 2011 Sales: $3,148m +11% CER Global
3,000 2,500 2,000 1,500 1 500 1,000 500 0
FY 10 US EST ROW Product Performance FY 11 W EUR EM ROW
23 23

EM ROW $450m +19% EST ROW $418m +35%

Growing 6 times faster than Seretide/Advair globally (in volume) US Gaining market share continuously in the US (+2.2 pts) despite a declining market and the launch of a 3rd competitor Symbicort share of total prescriptions reaching 20.3% in December 2011 ROW Gaining share in Japan with value share now reaching 32% two years post launch Fast growth in emerging markets (e.g. Russia +41% and Chi +27%) 41% d China 27%) Still growing (volume) in Europe more than 11 years after launch

W. EUR $ , $1,434m +0%

US $846m +17%

Symbicort: Steady share growth in US since launch i l h

25% 21.53% 20% 20.26% Sy ymbicort Mark Share (%) ket

15%

10%

5%

0% May/07

Oct/07

Mar/08

Aug/08

Jan/09

Jun/09

Nov/09 NRx Share

Apr/10

Sep/10

Feb/11

Jul/11

Dec/11

TRx Share

Product Performance

24 24

Nexium
FY 2011 Sales: $4,429m, -12% CER
5,000 4,500 4,000 3,500 3 500 3,000 2,500 2,000 1,500 1,000 500 0
FY 10 US EST ROW Product Performance FY 11 US $2,397m -11% EM ROW $730m +20% EST ROW $540m +10% W. EUR $762m -39%

W EUR EM ROW

US Generic penetration have significant impact on PPI market - decline in branded product p prescription demand p Cost effective promotion - No direct detailing support - Effective use of new channels Digital Customer service representatives Telemarketing ROW Emerging Markets +00% - Chi +38% China 38% Launched in Japan in September 2011 (PPI market in Japan was $2bn in 2010) W t Western Europe -39% E 39% - Generics are available in the majority of the European markets including UK, France, Spain, France Spain Italy and Germany
25 25

Nexium geographical dynamics

US
Predominantly generic PPI market Brand equity and innovative sales and marketing channels help drive profitability of Nexium

Western Europe
Data exclusivity expired 2010 Generics are available in all major European markets incl France, Spain, Italy, UK and Germany

Established ROW
Japan: Nexium Launched in Sept 2011 Canada: Ongoing patent litigation

Emerging Markets
Growth product China: Nexium i.v. included in 2009 NRDL listing Strong growth in 2011 listing. +38% CER

Product Performance

26 26

Iressa
FY 2011 Sales: $554m +32% CER Western Europe +147%
EM ROW $221m +34%

500

Strong launch uptake 80% of all 1st line EGFR M+ advanced NSCLC patients receiving IRESSA Emerging Markets +34%

400

300
EST ROW $204m +2%

g Including a 42% increase in China 1st line EGFR M+ approvals has been granted in majority of Asian countries Established ROW 1st line EGFR M+ approval received in Japan Q4

200

100

W. W EUR $127m +147% US* $2m -50%

0
FY 10 US EST ROW Product Performance FY 11

W EUR EM ROW
27 27

*NDA withdrawn in the US Jan 2011

Faslodex
FY 2011 Sales: $546m +55% CER
EM ROW $83m +28% EST ROW $6m +100%

Gl b l Global Value market share 60% (advanced breast cancer hormonal market) Faslodex 500mg now approved in 60 countries The conversion to the 500mg dose has been consistently successful across markets US & Western Europe together delivered 89% of global growth in 2011 Established ROW Launched in Japan in Nov 2011

500 400 300 200 100 0

FY 10 US EST ROW Product Performance FY 11

W. EUR $193m +48%

US $264m +71%

W EUR EM ROW
28 28

ONGLYZA Franchise: A new medication for type 2 di b t in a growing DPP4 class diabetes i i l
Approved in 68 countries (>45 launched) US, Canada, China, Mexico, India, Brazil, Australia, Russia and all EU US: Launched July 2009 - 2nd to US market - Kombiglyze XR (Onglyza & metformin) launched Jan 2011 - First once-a-day DPP4 plus metformin XR FDC EU: Launched October 2009 - 3 d DPP4 i hibit on th EU market 3rd inhibitor the k t - Komboglyze (Onglyza & metformin IR FDC) received marketing authorisation in Nov 2011

Est ROW / EM: Further Launches in ROW during 2012

Product Performance

Onglyza and dapagliflozin are jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

29 29

DPP4 class growing globally and have now surpassed TZDs DPP4's are now the leading BRANDED class DPP4 s by value(~$6bn*) and volume
NIAD Class Global Volume (PDOT) Share
NIAD Class Global Value (USD) Share

Metformin (MET), Sulfonylurea drugs ( ), thiazolidendiones (TZD), Dipeptidyl p p ( ), y g (SU), ( ), p p y peptidase-4 inhibitors (DPP4), alpha glucosidase inhibitors (AGI), Meglitinides (Glinide), Glucagon-like peptide-1 (GLP-1)

Product Performance

Source: AstraZeneca and Bristol-Myers Squibb. * Source: IMS Health MDART/MIDAS 3Q 2011 MAT.

30 30

ONGLYZA Franchise
FY 2011 Global Alliance Revenue: $211m +206% CER
200
EM ROW $14m +367% EST ROW $7m +250% W. EUR $34m +240%

150

US The ONGLYZA Franchise grew by 6.5 TRx share points during 2011 ~30% of US DPP4 market is FDC and ~ 1/3 of new patients receiving a DPP4 & metformin FDC are given Kombiglyze XR K bi l Kombiglyze XR success h lift d O l has lifted Onglyza franchise share of new patients to ~25% in the DPP4 class EU Later launches stronger e.g. in Greece, Norway, and Hungary, Patient Days of Therapy (PDOT) volume shares are above average l h b Est ROW / EM LatAM: launch performance g p good Launched in China Q4 2011 as the first DPP4 inhibitor F th approvals and l Further l d launches h expected during 2012
31 31

100

50
US $156m +189%

0
FY 10 US EST ROW Product Performance FY 11 W EUR EM ROW

ONGLYZA Franchise US market share performance

Total Rx Share
18%
16.45% 16 45% 17.20%

16% 14% 12%

TR Share Rx
11.79% 11 79%

11.67%

10% 8% 6%
5.53%

4% 2% 0%

4.66%

01-01-11

02-01-11

03-01-11

04-01-11

05-01-11

06-01-11

07-01-11

08-01-11

09-01-11

10-01-11

11-01-11

Onglyza

Kombiglyze XR

Onglyza Family

Product Performance

Source: IMS NPA Monthly data ending Dec 2012 Onglyza jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

12-01-11

32 32

Vimovo
Approved i US and EU A d in d
Delayed release NSAID naproxen with immediate release esomeprazole Overall 71 Regulatory Submissions, 41 Regulatory Approvals and 28 launches (US, UK, Netherlands (RMS), Canada, Bulgaria, Ireland, Latvia, Estonia, Lithuania Finland Slovakia, Sweden, Switzerland, Philippines, Estonia Lithuania, Finland, Slovakia Sweden Switzerland Philippines New Zealand, Belgium, Spain, Austria, Italy and others) for Vimovo. Global revenue of $34m in 2012 US - VIMOVO performance to date reflects the challenges of launching a branded product into a highly genericised US market EU - Majority of launches occurred in 2011 - Launch will follow pricing and reimbursement procedure for each country Row - New launches during 2012 in Brazil, Mexico, Russia and Australia
33 33

Product Performance

Vimovo
Approved i US and EU A d in d
Over 151 Million People Suffer From Osteoarthritis Pain1 Low Satisfaction
Up to 30% of OA patients switch or augment therapy in a year, mainly due to efficacy and side effects2 d id ff

GI Risk
More than 50% of OA patients on chronic NSAIDs are at GI Risk4 ~1 in 4 OA patients on NSAIDs are co-prescribed a PPI3

Non-Adherence Non Adherence

Up to 60% of patients are non-compliant with co-Rx p GPA5
H lth O Health Organisation, Gl b l B d i ti Global Burden of A th iti 2004 f Arthritis, Arthritis US VI DSP, 2009 3Adelphi Arthritis US VI DSP, 2006 4Sources: Us, EU4, Canada & Mexico Rxs, MAT 06/09. US Data: IMS LRx model, EU4 data: Cegedim EMR longitudinal data, Mexico & Canada IMS Detailed Medical Database, Midas 5Sturkenboom 2003
2Adelphi 1W World ld

Product Performance

34 34

Vimovo
Proven OA pain relief with built-in gastroprotection P i li f ith b ilt i t t ti
Demonstrated Significant Risk Reduction in Endoscopic GUs at 6 Months
30%
82% RR 71% RR

Approval based on studies 301 and 302, which demonstrated : - Significant endoscopic gastric ulcer risk reduction vs. EC naproxen - Gastric ulcers reduced even in presence of low dose aspirin - Significantly lower rate of discontinuation due to UGI AEs (including DU) vs EC naproxen

25% 20% 15% 10% 5% 0% 4.10%

23.10%

24.30%

GU Incidence

p<0.001

p<0.001
7.10%

PN400 n=218 218

EC-Nap n=216 216

PN400 n=210 210

EC-Nap n=210 210

PN400-301

PN400-302

Product Performance

35 35

BRILINTA/Prevalence of Acute Coronary Syndromes (ACS)

~3 5 million >1 4 million 3.5 >1.4

episodes of ACS reported in the p major 7 markets (EU*, US, Japan) in 2005

Hospitalisations CS for ACS in the US in 2005

About every y 26 seconds, an American will suffer a coronary event

About every minute, an American will die from a coronary event

*France, Germany, Italy, Spain, and United Kingdom.

1. Decision Resources Pharmacor Reports (STEMI, July 2006; NSTEMI/UA, July 2005). 2.Product Performance 2008;117:e25-146. Rosamond W, et al. Circulation.

36 36

The ACS opportunity

Source: Kantar Health EpiDatabase except for Germany, which sources from Decision Resources. 2011 estimates of incidence

37 37

BRILINTA Launch & Regulatory Status

Approved in 64 Markets

Launched* in 37 Markets
* commercially available y

Under Review in >30 Markets

Reimbursement in 20 Markets (+4 patient pay markets) Product Performance

As of 31st of Jan 38 38

BRILINTA Launch & Regulatory Status

Regulatory Approvals
BRILINTA regulatory approval in 64 countries with labels reflective of the PLATO trial. Provides access to 58% of global incident ACS population

Commercial Launch
BRILINTA commercial launches in 37 markets

Pricing & Reimbursement

BRILINTA reimbursement in 20 markets and 4 patient pay markets Provides access to 38% of global incident ACS population

Formulary / Protocol Access

BRILINTA formulary/protocol access varies by country

Provides access to 45% of global incident ACS population

Provides access to 12% of global incident ACS population

Product Performance
As of 31st of Jan

39 39

BRILINTA PLATO study

UA/NSTEMI (moderatehigh risk); STEMI (if primary PCI)
All receiving ASA; clopidogrel-treated or nave; randomised within 24 h of index event

(N=18,624) (N 18 624)

Clopidogrel If pretreated, no additional ld; if nave standard 300-mg ld, nave, ld then 75-mg od maintenance;
(additional 300 mg allowed pre-PCI)

AZD6140 (BRILINTA) 180-mg ld, then 90-mg bd maintenance

(additional 90 mg allowed pre-PCI)

6-12-month exposure Primary end point: Secondary end point:

CVD/MI/stroke patients intended for invasive management CVD/MI/stroke/recurrent ischaemia/TIA/other arterial thrombotic events

PLATO = A Study of PLATlet Inhibition and Patient Outcomes.

Product Performance

ASA = acetylsalicylic acid; bd = twice daily; CVD = cardiovascular disease; ld = loading dose; MI = myocardial infarction; NSTEMI = non-ST-segment elevation MI; od = once daily; STEMI = ST-segment elevation MI; UA = unstable angina

40 40

BRILINTA Reduction in CV death, MI or stroke

Product Performance
K-M = Kaplan-Meier Source: AZ US promotion material based on Plato study

41 41

BRILINTA Reduction in CV death

Product Performance
Source: AZ US promotion material based on Plato study

42 42

BRILINTA - Primary Efficacy Outcome ASA Maintenance Dose M i t D

16 14
Kaplan-M Meier estim mated rate (%) e

Tic: ASA High

12 10 8 6 4 2 0 0 60 120 ASA L ( 300 mg) : HR (95% CI), 0.79 (0.71, 0.88) Low (< ) ASA High (> 300 mg) : HR (95% CI), 1.45 (1.01, 2.09) 180 240 300 360
43 43

Clop: Cl ASA Hi h High Clop: ASA Low Tic: ASA Low

Days from randomisation

Product Performance
Source: Plato study

BRILINTA Pegasus Study

Further i F th investigating the potential of BRILINTA ti ti th t ti l f
Current treatment guidelines for acute coronary syndrome (ACS) patients recommend dual anti-platelet therapy for up to twelve months post-event The PEGASUS-TIMI 54 study will examine the long-term efficacy and safety of ticagrelor in patients who have sustained a heart attack from one to three years prior to enrolment Trial Design: - Randomised, double-blind, parallel-group study - 21,000 patients worldwide In addition to ticagrelor or placebo, patients will take once-daily, concomitant aspirin therapy (75 to 150 mg) Minimum treatment duration of 12 months The primary efficacy endpoint will be time to first occurrence of any cardiovascular event including CV death, non-fatal myocardial infarction or non-fatal stroke Data expected 2014
Product Performance
44 44

R&D &

R&D

How are we addressing the R&D productivity h ll ? challenge?

1. 1 Leadership and operating model

2.

Attrition analysis and portfolio review

3. 3

Organisational footprint

Ongoing* Ongoing

Ongoing

4.

Capability build and external science

R&D

* Further restructuring announced 2nd of Feb

46 46

1. One R&D organisation

Discovery and early development Di d l d l t

Late-stage Development L t t D l t

Internal and external opportunities

Innovative Medicines Units

Global Medicines Development p

Market

Innovative Medicines Units R&D Enabling functions

R&D

47 47

2. Changing therapy area focus

Build / Maintain Deprioritise

R&D

48 48

2. Stringent Selection Criteria

Right target engagement

Link between target / disease Predictive biomarkers Bioavailability and tissue exposure H Human PK/PD prediction di ti Differentiating safety Reactive metabolites Scientific evidence in lead indication Stratification of patient population Differentiated value proposition Embedded payer perspective

Right tissue exposure

Right safety

Right patients

Right commercial

R&D

49 49

2. Significant changes to the pipeline

Number of projects s

R&D

The AstraZeneca pipeline now includes [86] projects, of which 79 are in the clinical phase of development and 7 are either launched or approved.

50 50

3. Our R&D 2011 footprint

Small molecules Biologics

*Sodertalje, Sweden Alderley, UK *Montreal, Canada Boston, MA Wilmington, DE Gaithersburg, MD

St Petersburg, Russia , Molndal, Sweden Cambridge, UK Reims, France Osaka, Japan Shanghai, China Bangalore, India

San Francisco, CA

Global R&D Network g g p p Reducing Geographical footprint & Headcount Broader Technology base
l

R&D

*Announcement 2nd of Feb-Exit all R&D operations

51 51

4. Investing in new capabilities to enhance productivity

Integrated payer strategy

Clinical trial design and interpretation

Personalised healthcare

Predictive sciences

R&D

52 52

Portfolio highlights 2010/2011

Launched/Approved Submitted New Indications Phase 3/LCM Starts

TC-5214
Europe Japan Europe Europe, USA, Japan & China. (500 mg) US Europe & USA US & Europe Japan Europe 1st Line NSCLC Japan Europe Pegasus LCM Russia US, CAN, Brazil Further Markets Europe

Fostamatinib F t ti ib
Europe & USA

Dapagliflozin
Europe & US

NKTR-118 CAZ- AVI

(PUB) China

MEDI-3250
US

EU

China & other Markets

R&D

53 53

Late stage Projects ate ojects

R&D

Pipeline FY 2011- NCEs Phase III/Registration

Compound Mechanism Area Under Investigation Phase
US

Estimated Filing
EU Japan Emerging

Cardiovascular
Brilinta/Brilique ADP receptor antagonist Dapagliflozin# SGLT2 inhibitor arterial thrombosis diabetes III III Launched Filed** Launched Filed 1H 2013 1H 2013 Launched Filed

Neuroscience
TC-5214# NKTR-118# neuronal nicotinic channel modulator oral peripherally-acting opioid antagonist major depressive disorder (adjunct) opioid-induced constipation III III 3Q 2012 2H 2013 2015 2H 2013

Oncology
Caprelsa (vandetanib) Ranmark# (denosumab) VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity anti-RANKL Mab medullary thyroid cancer bone disorders stemming from bone metastasis III III Launched Filed 2014 Approved Filed

Infection
Q-LAIV Flu Vac (MEDI-3250*) Zinforo# (ceftaroline) live, attenuated, intranasal influenza virus vaccine (quadrivalent) extended spectrum cephalosporin with affinity to penicillin- binding penicillin proteins beta lactamase inhibitor/ cephalosporin seasonal influenza III Filed 4Q 2012

pneumonia/skin infections serious infections

III

Filed

3Q 2011

CAZ-AVI# (CAZ-104)

III

2014

2014

2014

Respiratory & Inflammation

Fostamatinib# spleen tyrosine kinase (SYK) inhibitor rheumatoid arthritis III 2H 2013 2H 2013 2H 2013 55 55

R&D

#Partnered

product, *sBLA in US, MAA in EU, ** CRL received in Jan 2012

Diabetes: A growing global problem

Type 2 Diabetes prevalence expected to grow from 285m to 438m by 2030 50-70% of patients are not controlled

Diabetes growing rapidly in U.S. current prevalence rate 10.3%

Europe prevalence is 6.9% with highest rates (>11%) in Germany, Austria, y, , Switzerland, and Portugal

Brazils prevalence will increase by twothirds by 2030 y

India and China will comprise nearly 33% of the worlds total patients with diabetes in 2030

CVGI

Source: WHO

56 56

The progressive nature of Type 2 Diabetes ultimately overwhelms medications lti t l h l di ti

Glycemic Control in an Illustrative Patient
Potential treatment change

First Agent HbA1c

Goal* A1c=<7 Goal** A1c=<6.5 Normal*** A1c=5%

~30 Years

Sources: ADOPT, UKPDS (*) According to the ADA; (**) according to the AACE/ACE; (***) according to the NIH (*) According to the ADA; (**) according to the AACE/ACE; (***) according to the NIH

CVGI

57 57

Dapagliflozin: new approach to diabetes

Submitted in US and EU in Dec 10
N Novel i l insulin i d li independent d t mechanism and site of action Potential benefit in uncontrolled patients with type 2 diabetes who require HbA1c reduction and the additional benefit of weight loss Effective at all stages of the disease and with widely used anti-diabetic medications
Glucose excretion enabled through SGLT2 inhibition

SGLT2 inhibition i hibiti

CVGI

Dapagliflozin is being jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

58 58

Dapagliflozin Regulatory status

Dapagliflozin FDA advisory committee outcome in July 2011, 6 Yes and 9 No, but acknowledged the need for new treatment options In Oct 2011, FDA extended the Prescription Drug User Fee Act (PDUFA) date for dapagliflozin by three months to January 28, 2012 A complete Response Letter was issued 19th of Jan by the FDA regarding the New Drug Application for dapagliflozin The complete response letter requests additional clinical data to allow a better assessment of the benefit-risk profile for dapagliflozin. This includes clinical trial data from ongoing studies and may require information from new clinical trials AstraZeneca and Bristol-Myers Squibb will work closely y y with the FDA to determine the appropriate next steps for the dapagliflozin application and are in ongoing discussions with health authorities in Europe and other countries as part of the application procedures

CVGI

Dapagliflozin is being jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

59 59

Dapagliflozin: A comprehensive phase 3 programme

T2D treatme ent paradigm m Diet and exercise Oral anti-diabetic medication(s) Oral anti-diabetic medication plus insulin

Monotherapy

Insulin alone

Dapagli iflozin clinical studies s

Monotherapy Initial combination with Metformin

H2H vs. SU Add-on Metformin Add-on SU Add-on TZD Add Add-on DPP4 (IIIb)

Add-on insulin +/- OAD

Special Patient Populations (Renal/CV) & Special Investigations (body composition)

6-month data from the monotherapy (study 13) and add-on to metformin (study 14) studies presented 2009 Study 6 (add-on to insulin) presented at ADA 2010 Data from 2 further studies (H2H vs SU add on to SU) presented at EASD 2010 vs. SU, add-on Phase III data from Studies 4, 14 and 21/34 presented at ADA in June 2011 12 dapagliflozin abstracts presented at the EASD in Sept 2011 Annual Meeting, including: eight primary clinical data presentations. FDA advisory committee held on the 19th of July 2011

CVGI

Onglyza and dapagliflozin are jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

60 60

Major Depressive Disorder (MDD) is a highly prevalent & debilitating disease with significant levels of unmet need

43
nd 2

million people worldwide affected by major depressive disorder1

leading cause of disability in ages 15 to 44 2

18 44%
Neuroscience
1 3

million patients are treated with drugs from a p g diagnosed population of 23 million globally 1

dont achieve remission after two sequential medications over a six months period3

Decision Resource Cognos Report August 2009 , 2 - WHO website key facts on Depression, Ref 2. Rush et al, Am J Psychiatry 2006; 163:19051917 Derived from steps 1 and 2, 56.1 patients (36.8+19.3) are remitters; 43.9 are non-remitters (44%)

61 61

TC-5214: opportunity in MDD

Phase 3 RENAISSANCE programme ongoing i
0

TC-5214 Phase 2b adjunct study demonstrated clinical efficacy in MDD improving over duration of trial
Mean ch hange in HAM Score fr M-D rom start of randomise treatment o ed t
-2 -4 -6 -8 10 12 14 16

Exciting Phase 2 results where TC-5214 demonstrated clinical efficacy in MDD The Phase 3 RENAISSANCE clinical program will sequentially readout from Q4 2011 until Q2 2012 Filings planned in the US in 2H 2012 and in the EU in 2015

** *** ** ** **

PBO + CIT TC-5214 + CIT p < 0.01 P < 0.0001

Impr rovement

***
1 2 4 6 8

Week since randomisation

*HAM-D = Hamilton depression Score

Neuroscience

62 62

TC-5214 Key Milestones

2011
US MDD Adjunct
Renaissance 2 (Flex) Renaissance 3 (Flex) Renaissance 4 (Fixed) Renaissance 5 (Fixed) Renaissance 7 (LTS)

2012

2013

2014

2015

H2
PLANNED SUBMISSION

EU/RoW MDD Adjunct

Additional studies to meet EU regulatory requirements: Long term efficacy, Elderly

PLANNED SUBMISSION

Monotherapy

Phase II trial

H2
PHASE III DECISION POINT

Neuroscience

63 63

TC-5214: Phase 3 RENAISSANCE Program

RENAISSANCE 2 RENAISSANCE 3 RENAISSANCE 4 RENAISSANCE 5 RENAISSANCE 7

Study design S Geographic location Planned number of patients to be screened

Flexible dosing

Flexible dosing

Fixed dosing

Fixed dosing Global (no US or India)

Long term safety f

US and India

Europe

US and India

US

940

940

2234

2236

2000

Target number of evaluable patients

288

288

684

684

At least 300 for 6 months & 100 for 1 year 1-4mg TC-5214 BID or placebo

Dose

1-4mg TC-5214 BID or placebo

1-4mg TC-5214 BID or placebo

0.5 mg, 2 mg or 4 mg TC-5214 BID or placebo NCT01153347

0.1 mg, 1 mg or 4 mg TC-5214 BID or placebo NCT01197508

ClinicialTrials.gov identifier

NCT01157078

NCT01180400

NCT01152554

RENAISSANCE 3 & 2: Top line data announced on the 8th of Nov and 20th of Dec. Dec The studies did not meet their primary endpoints of change on the Montgomery-sberg Depression Rating Scale (MADRS) after eight weeks of treatment with TC-5214 as compared to placebo
64 64

Fostamatinib Rheumatoid Arthritis

Fostamatinib is:
the first oral spleen tyrosine kinase inhibitor in development as a potential treatment for RA thought to reversibly block signaling in multiple cell types involved in inflammation and tissue degradation in RA

Phase IIb data (TASKi 2) published in the New England Journal of Medicine, demonstrated1
anti-TNF like levels of efficacy Main adverse events of interest are GI tolerability, AST/ALT changes and raised blood pressure all of which appeared to be manageable at doses being investigated in phase 3 TASKi3 study in patients who failed biologic therapies failed to meet primary endpoint in phase 2
Believed to be due to technical issues with the study design

Fostamatinib long term extension (LTE) study presented at ACR in Nov Fostamatinib is in Phase III development for the treatment of RA in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX) Initial regulatory filings anticipated in 2013 in US & EU Inflammation
New England Journal of Medicine, An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis, Weinblatt ME, Kavanaugh A, Genovese MC, et al. September 30, 2010; 363:1303-1312
1- The

65 65

Rheumatoid Arthritis is a prevalent & debilitating di ith i ifi tl l f t d disease with significant levels of unmet need

20 9 7 3
Inflammation

million people worldwide affected b RA1 illi l ld id ff d by

Million RA patients treated with disease-modifying therapy (traditional and biologic)2,3

Million RA patients (approx. 80%) do not achieve remission with a traditional disease modifying anti-rheumatic drug (DMARD) alone4 Million RA patients are treated with biologic therapy following inadequate response to a DMARD (accounting for $12 bn in sales, approx. 90% of the RA market2,3)

1 WHO report: The global burden of rheumatoid arthritis in the year 2000 http://www.who.int/healthinfo/statistics/bod_rheumatoidarthritis.pdf 2 Decision Resource Pharmacor 2010 , 3 IMS Health MIDAS sales database 4 Blumberg SN, Fox DA. Rheumatoid arthritis: guidelines for emerging therapies. Am J Manag Care 2001 ; 7 (6): 617 -26

66 66

Fostamatinib opportunity in RA
Target Population Patients who have an inadequate response to traditional diseasemodifying anti-rheumatic drug (DMARD) therapy
Profile in phase II I Improved outcomes in RA patients with d i i ih methotrexate background treatment, as measured by ACR and DAS p Fast onset of action - 36% of patients achieved a response within 1 week Initial evidence of preventing further bone and cartilage damage Manageable safety and tolerability profile Improved patient QoL Oral formulation No administration pain as associated with injected therapy No need to visit hospital / physicians office for infusions ffi f i f i

Inflammation

67 67

Fostamatinib demonstrates efficacy in RA patients with inadequate response to methotrexate

Robust TASKi2 phase 2b trial reproduces anti-TNF like efficacy seen in phase 2a

Placebo acebo
Ref:

Fostamatinib 150 mg po qd osta at b 50 g

Fostamatinib 100 mg po bid osta at b 00 g bd

Inflammation

The New England Journal of Medicine, An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis, Weinblatt ME, Kavanaugh A, Genovese MC, et al. September 30, 2010; 363:1303-1312

68 68

Fostamatinib phase 3 development plan

The phase III programme, OSKIRA, is designed to investigate fostamatinib as a treatment for RA in patients with an inadequate response to DMARDs, including methotrexate
FPI Sept 2010 MTX-IR, 12 month MTX combination, n 900 n~ DMARD-IR, 12month DMARD combination, n ~ 900 aTNF-IR, 6 month MTX combination, n~ 450 LONG-TERM EXTENSION n~ 2100 (incl. 500 ex PhII) ( ) Monotherapy (Phase IIb), 6 month DMARD naiive and IR, n ~ 250 ( g Q (began Q1 2011) ) Japanese Phase I study (US) NDA & MAA 2013

Inflammation

* First data available late 2012 / early 2013

69 69

NKTR-118: Opioid Induced Constipation (OIC)

OIC is a common and potentially debilitating adverse effect associated with opioid analgesic use - 250 million opioid prescriptions were written f treatment of acute and chronic pain illi i id i ti itt for t t t f t d h i i in 2010 in the United States alone1 - For those patients who take opiates for long term pain management, approximately 40-50 40 50 percent will develop constipation2 - Only about 40-50 percent of those patients experience effective relief from the current treatment options that include prescription and over-the-counter laxatives and stool softeners3,4,5. NKTR-118 is an oral peripheral mu-opioid antagonist , under investigation for the treatment of opioid-induced constipation (OIC). It is designed to relieve OIC without impacting pain relief relief.

NKTR-118 is part of the exclusive worldwide license agreement announced on September 21, 2009, between AstraZeneca and Nektar Therapeutics.

1 2 3

Neuroscience

4 5

IMS MAT. December 2010. Thomas, J. Opioid-Induced Bowel Dysfunction. Journal of Pain and Symptom Management. 2008;35(1):103-113. Bell, Bell T et al OBD symptoms impair quality of life and daily activities regardless of frequency and duration of opioid treatment: al. activities, results of a U.S. patient survey (PROBE survey). Poster presented at The 25th Annual Scientific Meeting of the American Pain Society. San Antonia, TX, USA. Pappagallo, M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001:182;S11-S18. Fakata, K. Peripheral Opioid Antagonists: A Therapeutic Advance for Optimizing Opioid Gastrointestinal Tolerability. The Journal of Family Practice. 2007;56:S1-S12.

70 70

NKTR-118 significantly increases the frequency of spontaneous b f t bowel movements and reduces l t d d time to first SBM in phase 2 studies
Change from Baseline in Spontaneous Bowel Movements (SBMs/week)
NS P = NS
Ch hange in SBM (SE)

Median Time (hrs) to First SBM

P = 0.001 P < 0.002

P = 0.002

P = 0.0001
Time (hrs) to First SBM ( S

60 50 40 30 20 10 0
5 mg 25 mg 50 mg 6.2 6.6 2.9 28.2 48.6 44.9

5 4 3 2 1 0
5mg 25mg 50mg

4.4 3.6 2.6 26 1.8 1.9 1.9

Placebo

NKTR-118

Placebo

NKTR-118

Week 1 of DB Treatment P-values based on a Wilcoxon Test

P-values based on a log rank test g

Neuroscience

Webster L et al. ACG 2009

71 71

NKTR-118: KODIAC - Ongoing Phase 3 Program

The Global Phase 3 Program* Commenced in g March 2011 - Two 12-week, randomized, placebo-controlled efficacy studies (N=630 per trial) with One 12-week Extension (N 630 12 week study (N=633) - An open-label, randomized, long term safety study with a usual care comparator arm (N=1135) - One efficacy study in patients with cancer related pain (N=340) AZ responsible for the full development of NKTR-118 including clinical, regulatory, CMC and commercialization activities Health Authority filings planned by AZ in 2013

*Clinicaltrials.gov ref: NCT01323790 , NCT01309841, NCT01384292, NCT01336205, NCT01395524

Neuroscience

72 72

Caprelsa (vandetanib) Approved for treatment of advanced medullary thyroid cancer f d d d ll th id

Thyroid cancer is a rare form of cancer. MTC represents 5 to 10% of total thyroid cancer cases About half of MTC patients have locally advanced and/or metastatic cases. MTC (aMTC). - US - estimated 45,000 new thyroid cancer cases each year, up to 2000 new MTC patients a year - Europe - thyroid cancer affects approximately 48,000 individuals annually, with an estimated mortality rate of 6,300 patients each year (GloboCan 2008) FDA approval on the 6th of April 2011 - only medicine to receive FDA approval specifically for use in patients with advanced medullary thyroid cancer and brought to market under Orphan Drug Designation in the US Caprelsa significantly improved progression free survival in patients with medullary thyroid cancer (MTC) in the ZETA phase 3 trial p - Data presented at ASCO 2010 Received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Q4 2011

Oncology

73 73

Anti-Infective portfolio that covers ab broad spectrum of opportunities d t f t iti

Spectrum of Activity
Resistant G R i t t Gram+ + Gram+ G + Gram G Resistant Gram R i t tG

MRSA MDRSP

S. S pneumoniae i S. aureus

H. influenzae E. coli K. pneumoniae

ESBL P. P Producing aeruginosa Gram

Ceftaroline Ceftaroline + NXL104 CAZ AVI

Infection

74 74

Zinforo (ceftaroline): A next generation cephalosporin antibiotic h l i tibi ti

Phase III programme targeting:
- Complicated skin and soft tissue infections (cSSTI) - Community-acquired pneumonia (CAP) - Demonstrates bactericidal activity against a broad range of pathogens commonly implicated in cSSSI and CAP, including methicillin-resistant Staph. Staph aureus (MRSA) and penicillin-resistant Strep pneumoniae (PRSP) penicillin resistant Strep.

Collaboration with Forest Laboratories started August 2009

- AstraZeneca to co-develop and commercialize in all markets outside US/Canada/Japan - Financial terms not disclosed

Infection

75 75

Complicated skin and soft tissue infections (cSSTI) d ( SSTI) and community acquired pneumonia it i d i (CAP)
cSSTI CAP

Infection

76 76

Zinforo: A next generation cephalosporin antibiotic tibi ti

Submitted in EU Dec 10
Demonstrated good efficacy in Phase 3 cSSTI and CAP Differentiating attributes - extended spectrum coverage, incl. MRSA activity in skin, coupled with a favourable tolerability profile
cSSTI

Noninferiority

1o Endpoint 10% NI margin Response (% Difference)

Population -10

10

20

Modified intent-to-treat CANVAS 1 Clinically evaluable Modified intent-to-treat CANVAS 2 Clinically evaluable FOCUS 1 Modified intent-to-treat Clinically evaluable Modified intent-to-treat FOCUS 2 Clinically evaluable
1.2

CAP

Favours Comparator

Favours Zinforo

Infection

77 77

CAZ AVI: to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies
Globally, Globally over 1m patients a year suffer from infections known or suspected to be resistant to cephalosporins which are routinely used to treat Gram-negative infections. This figure is expected to grow by >25% over the next decade CAZ-AVI CAZ AVI combines a broad spectrum cephalosporin (ceftazidime) and a novel broad-spectrum beta-lactamase inhibitor (avibactam, formerly NXL104) AstraZeneca and Forest will initiate Phase III programme for CAZ AVI to treat serious Gram-negative bacterial infections including Complicated IntraAbdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI) p g g pp global regulatory filings in 2014 g y g The trial programme is designed to support g and will include five Phase III trials, based on positive results from two Phase II trials In the collaboration, development costs will be shared between AstraZeneca collaboration and Forest Forest will have the rights to commercialise CAZ AVI in North America, AZ has rights to commercialise CAZ AVI in rest of world
78 78

Infection

Phase 3 development decisions

Assets
AZD1981 (CRTh2 receptor antagonist) t t i t) AZD8931 (erbB kinase inhibitor) AZD9773 (anti-TNF-alpha polyclonal antibody) AZD6244 Selumetinib
(MEK inhibitor)

Area under investigation

Asthma / COPD Breast cancer/Solid tumours Severe sepsis NSCLC / Solid tumours S lid t Polymicrobial infections Solid tumours Glioblastoma

CXL
(beta lactamase inhibitor and cephalosporin)

MEDI1123 Tremelimumab
(CTLA-4 monoclonal antibody) (anti-PDGFR-alpha MEDI575 (anti PDGFR alpha mAb)

New target

Follower

R&D

79 79

Phase 3 development decisions: 1 example

Assets
AZD1981 (CRTh2 receptor antagonist) t t i t) AZD8931 (erbB kinase inhibitor) AZD9773 (anti-TNF-alpha polyclonal
antibody)

AZD6244 selumetinib Unmet medical need

Non-small cell lung cancer

AZD6244 Selumetinib
(MEK inhibitor)

CXL
(beta lactamase inhibitor and cepholasporin)

MEDI1123 Tremelimumab
(CTLA-4 monoclonal antibody)

Asthma with MEK inhibitorallergic component i hibit Leading cause of cancer mortality 25% have KRAS mutation and poor prognosis Breast cancer Phase 2: Significant improvement in Progression-free survival Severe sepsis p Trend for improvement in overall survival

MED575 (anti PDGFR alpha mAb) (anti-PDGFR-alpha

New target Follower

KRAS mutation non-small cell lung

R&D

80 80

Strategy Update & Planning Assumptions 2012+

81

Planning Assumptions

Corporate Strategic priorities

Making the most meaningful difference to patient health through great medicines
Pipeline Deliver the business Business Shape People

Increase output Drive productivity & efficiency

Growth of current products Successfully launch the new products Drive growth in emerging markets Develop innovative p channels to meet customer needs

Implement asset strategy & LEAN Drive efficiencies in Sales & Marketing and G&A d Focus Capex on productivity improvements p

Innovation Accountability Lean & agile Value orientation

- Disease area focus - Reduce site footprint - Externalisation - Build stronger relationship l ti hi with payers

Collaboration

Manage for long term shareholder value long-term

Our values

Planning Assumptions

82 82

Key planning assumptions remain robust

Pharma sector can grow at least in line with real GDP, which will grow over th planning h i hi h ill the l i horizon Downward pressures from government interventions in the marketplace increased in 2011 - Do not, as yet, represent a sustained step-change in evolution of these pressures AstraZeneca assumptions - No material M&A or disposals
Astra Tech sale in Q3 2011

- No premature loss of market exclusivity for key products - No material change in Fx rates for principal currencies vs average January 2010 rates y
Euro has significantly weakened vs USD

Planning Assumptions

83 83

Guidance for 2012 (Core basis)

Revenue Gross Margin Core Pre-R&D Margin Low double-digit decline at CER Below 2011, but above 80% Below 2011, but upper half of mid-term planning range (48%-54%) In line with 2011 Low double-digit decline vs 2011 Reported tax rate around 24% Range $6.00 to $6.30

Net Finance Expense Other Operating Income Tax Rate Core EPS

Planning Assumptions

84 84

Currency basis for 2012 guidance

Currency: January 2012 average rates: - $1 = 0.645 - $1 = EUR 0 775 0.775 - $1 = SEK 6.849 - $1 = JPY 76.923 Actual 2012 rates may differ materially from January 2012 rates upon which guidance is based 2012 currency sensitivity estimator is available at www.astrazeneca.com

Planning Assumptions

85 85

Estimated impact of currency movements on sales and earnings l d i

Estimated impact of a 10% appreciation of the respective currency against the USD
Sales EUR GBP SEK JPY Other Currencies TOTAL 1.9% 1 9% 0.2% 0.1% 0 1% 1.1% % 2.7% 6.0% Core earnings 3.5% 3 5% -2.2% -2 6% 2.6% 1.4% 4.9% % 5.0%

Planning Assumptions

86 86

Planning Assumptions 2010-14: Update

G Grow the Business th B i - Revenue in the range of $28bn to $34bn per annum over the period Centre of gravity lower half of range g g forward g y g going - Risk adjusted revenue contribution from the recently launched and pipeline products lowered to the range of $2bn to $4bn Reshape the business - Maintain gross margin >80% - C Core Pre-R&D operating margin in the range of 48-54 percent & f - Restructuring programmes on track. Phase 3 announced 2 Feb 2012 Cash generation and investment - Achieving revenues and margins within planning range will drive strong cash flow - Reinvest 40 to 50% of after tax pre-R&D cash flow to drive future growth and value - C h returns t shareholders via progressive di id d and periodic Cash t to h h ld i i dividend d i di share repurchases
Planning Assumptions
87 87

Deliver the business

Strategic Initiatives
Grow market share of key brands that retain exclusivity: - Crestor q - Seroquel XR - Symbicort Successfully commercialise recent launches and the next wave wave* - NKTR-118 - ONGLYZATM - TC-5214 - BRILINTA ( ) - Zinforo (ceftaroline) - Vimovo - Caprelsa (vandetanib) CAZ AVI - Fostamatinib - Dapagliflozin Planning assumptions 2010-2014 Revenue in the range $28bn-$34bn per annum over th period the i d Centre of gravity lower g going half of the range g g forward Risk adjusted contribution of $2bn$4bn from the recently launched and pipeline products Emerging Markets business ~25% of revenue in 2014
88 88

Sustain double digit growth in emerging markets - Drive growth and new launch portfolio - Broaden portfolio to include branded generics

Strategy

* Updated to reflect recent pipeline changes Onglyza and dapagliflozin are jointly developed and marketed by AstraZeneca and Bristol-Myers Squibb.

Business shape
Strategic Initiatives
Maintain gross margin >80% - Complete asset strategy & API outsourcing - Drive LEAN Sigma Improve Sales & Marketing effectiveness and efficiency - New channels and approaches pp - Technology investment - Quality initiatives Increase G&A cost efficiency and flexibility - Process improvement and automation - Consolidation & selective outsourcing Procurement savings across all functions Focus on working capital management Core pre-R&D operating margin in the range of 48-54% Planning assumptions 2010-2014

Strategy

89 89

Driving ROI from R&D

Investment period Function costs

Reduce

Returns period Supply chain capacity Sales and Marketing (mature markets) N Non-customer f i t facing roles l

Site footprint

New talent
Invest/Innovate

New commercial channels Emerging Markets - Sales and Marketing - Manufacturing

90 90

Critical capabilities Externalisation

Cash generation & Investment

Reinvest 40 to 50% of after-tax pre-R&D cash fl ft t R&D h flow to drive future growth and value Internal and external R&D Tangible assets and information technology

Business f B i focus on cash h flow generation

Residual R id l cash flow h fl available for

Achieving revenue and Core pre-R&D margins in planning range Delivering restructuring programmes Tight management of working capital, tax & interest

Specific business needs Debt repayment Progressive dividend policy Share repurchases

Strategy

91 91

2010-2014 in summary
Reinvest 40-50% 40 50%
Pre-R&D p post tax cash flow

Marketed Products

Revenue $ $28-34bn

Pre R&D Margin Pre-R&D 48-54% 48 54% Margin

48-54%

Pre-R&D post tax cash flow

Other business needs & debt service

Working W ki capital, Tax & it l T interest management Shareholder distribution

Planning Assumptions

92 92

2011 Strong Cash Generation: Use of Cash

$bn, Act RoX 18 16 14 12 10 8 6 4 2 0 2011 Opening Net Cash Pre R&D Post tax cash flow After tax R&D* Capex Dividends Net SBB 2011 Closing Net Cash AstraTech

40% Reinvestment Rate

3.3 1.8

$9.4bn Return to Shareholders

1.1 3.8 11.1 5.6

3.7

8.3

2.8

93

* R&D includes internal R&D expenditures, net of tax and depreciation/amortisation,and externalisation.

93 93

Shareholder Distributions

Progressive dividend policy

Maintain or grow dividend each year Annual dividend to reflect earnings prospects over entire cycle, not just one year in isolation & cycle cover may vary, with target of an average of 2-times cover (ie 50% payout ratio) over the cycle, based on reported earnings (before restructuring)

Dividend for 2011: $2 80 vs $2 55 2010 (+10%) $2.80 $2.55

Second interim dividend 2011 $1.95

Distribution policy and financial strategy to balance needs of business investment, financial creditors and shareholders i t t fi i l dit d h h ld The Board to keep under review the opportunity to return surplus capital via periodic share repurchases
2011: $5.6bn net share repurchases. Original target in 2011: $4bn net augmented by net proceeds from the sale of Astra Tech. 2012 target: $4.5bn net, subject to business needs

Net cash distributions to shareholders 2011

Increased by +71% to $9.4bn through net share repurchases of $5.6bn & $3.8bn through the payment of the second interim dividend from 2010 and the first dividend from 2011

Planning Assumptions

94 94

Restructuring Programme: Phase 1 Complete 2007-2009 2007 2009

Headcount Impact 2007-2009 Global Supply Chain SG&A R&D Total 4,250 6,750 1,600 12,600 Programme Cost 2007-2009 $m (1,003) (1,216) (288) (2,506) 2,400 Annual benefits 2010 $m

Strategy

95 95

Restructuring Programme: Phase 2 Complete 2010-2011 2010 2011

Headcount Impact p 2010-2012* Global Supply Chain SG&A R&D Total 1,700 3,430 3,730 8,860 Programme Cost 2010-2011 $m (198) (782) (1,122) (2,102) 1,900 Annual benefits 2014 $m

Programme cost: $1.2 billion was charged in 2010, and $0.9 billion in 2011 $1.0 2011 Benefits: Realised $1 0 billion through end of 2011, and are on track to deliver about [two thirds] of the remaining benefits by end 2012, with the remainder by 2014 *Headcount Impact: Some employees for which charges relate remain with the business at Dec 31st 2011 but will leave in 2012

Strategy

96 96

Net headcount developments: 2006-2011

Global Supply Chain SG&A R&D AstraTech R&D Reinvestment Emerging Other Markets Reinvestment

(3,000)
Wave 1 & 2 20,500*

-9,600 Net

(8,000)

(13,000)

(18,000)

(23,000)
Headcount Dec 31st 2006 (66,800) Headcount Dec 31st 2011 (57,200) *Some Employees affected by the Wave 2 programme are still employed at Dec 31st 2011 Includes the acquisition of MedImmune

Strategy

97 97

Restructuring Programme: Phase 3 2012-2014

Headcount Impact p 2012-2014* Global Supply Chain SG&A R&D Total 1,350 3,750 2,200 ~ 7,300 Programme Cost 2012-2014 $m** (500) (800) (800) (2,100) 1,600 Annual benefits 2014 $m

*Subject to completion of requisite consultation process. ** We charged $261 million of this $2.1 billion Phase 3 restructuring charge during fourth quarter 2011 [Headcount Impact: Some employees for which charges relate remain with the business at Dec 31st 2011 but will leave in 2012.] [Includes roughly $200m of demolition costs.]/[Cash vs non cash]

Strategy

98 98

Newsflow 2011 e s o 0

Newsflow

Q1 2012- Q2 2013 Newsflow

Q1
BRILINTA/Brilique BRILINTA/B ili EU launches & ROW Further submissions/approvals Dapagliflozin CHMP decision ONGLYZA/KOMBIGLYZE Further submissions/approvals/launches Zinforo Further submissions in ROW EU decision TC 5214 Sequential read out of further Phase III data RENAISSANCE 4 and 5 Second interim dividend 2011 Ex dividend date AstraZeneca quarterly results and AGM 15th Feb

Q2

Q3

Q4

Q1 13 Q2 13

26th Apr Fostamatinib Initial data from OSKIRA program NKTR-118 Initial data from KODIAC program

26th Jul

25th Oct

Newsflow

100 100

AstraZeneca st a e eca

Historic performance & Shareholder returns

History

AZN: Strong financial performance 1999-2011

Cost control Operating leverage
550 500 450 400 350 300 250 200 150 100 50 0
Sales +7% Core Op Profit +12% Core EPS +14%

CAGR

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

History

Source: AZ annual reports, implied core margins

102 102

Strong cash generation: 1999-2011

($bn) 100 90 80

31

Reinvestment of 44% of Operating cash flow ( (excluding major g j acquisitions)

15
70 60 50 40 30 20 10 0 -10 1999 Net Funds Pre-R&D Post Tax Cash Flow After Tax R&D* Capex Merck Acquisitions Distributed to Payments & Disposals Shareholders Other 2011 Net Funds

111

13 26 Div

23 SBB

Planning Assumptions History

* R&D includes internal R&D expenditures, net of tax and depreciation/amortisation,and externalisation. Source: AZ annual reports

103 103

Total Shareholder return AZ vs. Peers since 2006

160%

Index Annua growth rate (%) al

150% 140% 130% 120% 110% 100% 90% 80%

AZN Total Return FTSE 100 Average Total Return Peer Average Total Return

Note: Peers line data represents an average of the total shareholder return for (including AZ) those companies which AZ classifies as its peers Abbott, BMS, Eli Lilly, GSK, J&J, Merck, Novartis, Pfizer, Roche and Sanofi

History

Source: Morgan Stanley

104 104

AZ 10 year dividend growth vs. peers

400% 350%

Index Annual growth rate (%) x g e

300% 250% 200% 150% 100% AZN Peer average GSK

Note: Peers line data represents an average of dividend growth for (including AZ) those companies which AZ classifies as its peers Abbott, BMS, Eli Lilly, GSK, J&J, Merck, Novartis, Pfizer, Roche and Sanofi

History

Source: Bloomberg

105 105

Key Industry Growth Drivers

106

Growth Drivers

Pharmaceutical industry growth drivers

Emergence of expanded populations in new markets

Continued unmet medical need

Increasing and ageing populations Continued scientific and technological advance

Growth Drivers

107 107

The global population is ageing, with older patients consuming more healthcare than younger patients
Global population aged 65 and older, millions older
65-69 70-74

Ratio of healthcare costs of older patients relative to 50-64 age group 50 64

US

977

75-79 80-100 65 69 65-69 70-74 75-79 80-100 65-69 70-74 70 74

477

Canada

UK

2005

2030

75-79 80-100

Source: World Population Prospects: The 2005 Revision http://esa.un/unpp

0x

2x

4x

6x

8x

10x

12x

Growth Drivers

Source: Kotlikoff & Hagist, Dec 2005

108 108

Worldwide, the top 10 pharmaceutical therapy areas are expected to grow by $100bn 2010 16 t dt b $100b 2010-16
120,000

Emergence of expanded 80,000 populations in new markets

60,000 40,000

100,000

Continued unmet medical need

2016 2011

20,000

Increasing and ageing populations

Continued scientific and technological advance

Growth Drivers

Source: Evaluate Pharma

109 109

Emerging market GDP set for further expansion i

G7 countries
25,000

E7 countries

Real GDP (US$ billions)

Emergence of expanded 20,000 populations in 15,000 new markets

10,000 10 000

Continued unmet medical need

and ageing populations

-

5,000 Increasing

Continued scientific and technological advance

2010

2016-2042 ave.
110 110

Growth Drivers

Source: Global insight quarterly

GDP growth drives growth in pharmaceuticals spend h ti l d

Pharma spend Ph d per capita US$, 2008
700 600 500 400 300 200 100 0 0

United States (off scale) GDP/cap 47,369 Pharma spend/cap 954

France Japan Germany Spain Italy Emerging markets United Kingdom

Brazil China India

Turkey Mexico Russian Federation

10,000 20,000 30,000 40,000 50,000 60,000 70,000

GDP per capita US$ 2008 US$,

Growth Drivers

Note: R2=0.8, N=63, United States outlier excluded from the regression analysis. Source: World Market Monitor; IMS.

111 111

Emerging markets are forecast to contribute ~70% of pharma growth during 2010 2015 70% 2010-2015

Growth Drivers

112 112

Exploding emerging market middle-class

BRIC population with household income above $5,000

+21% p.a.

2004 270 million

Growth Drivers

2009 900 million

2014E 1,864 million

113 113

Source: Economist Intelligence Unit, 2010, China NSBA, Indian NFHS, RAND, Brazil PNAD

The emerging market opportunity is distributed across a l large number of markets b f k t

Emerging market p g g pharma sales, 2009 ,

Brazil, Russia, India, Mexico & Turkey

~$60bn
( 33%) (~33%)

~$90bn
(~50%)

Small & mid-sized EMs

~$30bn $30b
(~17%)
China

There is a lot more than BRIC-MT

Growth Drivers
Source: IMS

114 114

While individual markets have ups and downs, the th portfolio of markets provides steady, tf li f k t id t d strong growth
Standard deviation of year-on-year GDP growth rates 2004-2010 (%pts) rates,
8.6

4.9 3.7 2.6 1.7 1.9 19 1.5 1.7

5.3 3.8 2.8

5.3 3.7

3.6

3.2 2.3 0.7 2.0 20 2.4 1.8

2.0

Portfolio of ~20 emerging markets

The variation of the portfolio is lower than almost all markets individually

Growth Drivers

Source: IMS

115 115

AstraZeneca has built a truly global emerging markets prescription drug business k t i ti d b i

2011 Sales1
Asia-Pacific

$2.2bn
Latin America

$1.5bn
Growth Drivers
1 2

CEEMEA2

$2.1bn $2 1bn
Actual exchange rate. Central and Eastern Europe, Middle East, and Africa (including Turkey); Source: AZ

116 116

Both BRIC-MT and small and mid-sized emerging markets h k t have contributed significantly to our growth t ib t d i ifi tl t th
2004 11 2004-11 AZ emerging markets sales $5.8bn Absolute growth $3.9bn CAGR 17%

$3.6bn

$2.9bn

$1.8bn

15%

$1.9bn $ $1.9bn Small and mid-sized EMs BRIC-MT $1.1bn $0.8bn 2004 $1.7bn

$2.9bn

$2.1bn

20%

2007

2011
117 117

Growth Drivers

Actual exchange rate. Source: AZ internal

Brands dominate the market as brands are the best b t proxy for quality f lit
Emerging market sales1, 2009, Ex-manufacturer
~$50bn ( (~28%) %) ~$90bn (~50%) ~$30bn (~17%) ~$180bn

~$10bn ( 5%) $10bn (~5%)

Commodity generics Branded generics Branded originals Patented originals Total

Growth Drivers

Across 17 selected markets (China, Turkey, India, South Korea, Brazil, Mexico, Poland, Russia, Taiwan, Hungary, Romania, Egypt, Algeria, Saudi Arabia, South Africa, Ukraine, UAE). Source: IMS; AZ analysis.

118 118

Across emerging markets we have a highly successful portfolio of brands f l tf li f b d

AZ product sales in emerging markets, 2011
$730m $661m $459m $450m $384m $352m $324m $310m $298m $219m

Growth Drivers

119 119

Brand lifecycles are fundamentally different than in t bli h d th i established markets k t

Despite expiry of key p p p y y patents in most markets, p , product g growth can be sustained
Example: Sales by country, % value growth p.a. Brazil Diprivan China Losec Turkey Pulmicort
+11% +25%

$33m $69m

+13%

$158m $11m

$15m $15

$23m

$16m $7m

$91m

2004

2007

2011

2004

2007

2011

2004

2007

2011

~9 competitors LOE1: 1999

>130 competitors LOE1: 2001

~8 competitors LOE1: 2001

Growth Drivers

Loss of Exclusivity. Source: AZ; IMS; EvaluatePharma.

120 120

We have delivered improving profitability across emerging markets i k t

AZ pre-R&D emerging markets operating margin (excluding central costs), indexed t 2011 margins i established markets i d d to i in t bli h d k t
73%

65% Our current emerging markets margins are similar to our Europe business 6-7 6 7 years ago

55%

2004

2007

2011

Growth Drivers

Source: AZ internal

121 121

Our strategy in emerging markets has th h three elements l t

Emerging markets strategy

A
Continue to grow our presence in the large BRIC-MT markets

B
Extending our geographic footprint by increasing our involvement in high-growth small and mid-size markets

C
Broaden portfolio to selectively include branded generics

Growth Drivers

122 122

Our goal is to continue double-digit growth, with emerging markets becoming ~25% of ith i k t b i 25% f AZ sales by 2014
AZ emerging markets revenue goal
$12bn

$8bn

$4bn

$0bn

2009

2014
123 123

Growth Drivers

Q4 Financial & Key Product Performance

Product Performance

Headline results Q4 2011

Q4 2011 $m Q4 2010 $m Actual growth CER growth

Revenue Core Operating Profit Core EPS

Restructuring MedImmune/Merck amortisation Legal and Other L l d Oth

8,656 2,990 $1.61

($0.36) ($0.08) ($0.01) ($0 01)

8,617 2,865 $1.39

($0.22) ($0.07) $0.05 $0 05

0% +4% +16%

0% +1% +12%

Reported EPS

$1.16

$1.15

0%

-5%

Financial Performance

Performance

125 125

Regional revenue performance Q4 2011

Q4 2011 $m Global Revenue US Western Europe Established RoW Emerging Markets 8,656 8 656 3,643 2,005 1,600 1 600 1,408 CER % 0% +5% -15% +3% +10% CER $m +19 +189 -350 +45 +135

Financial Performance

Performance

126 126

Key brand revenue summary Q4 2011

Q4 2011 $m CER %

Crestor Seroquel
Seroquel IR Seroquel XR

1,771 1 771 1,546

1,148 1 148 398

+11% +15%
+12% +27%

Nexium Symbicort

1,067 839

-13% 13% +13%

Financial Performance

Performance

127 127

Core margin: Q4 2011

$m Revenue Core Gross Margin Distribution Core SG&A C Core Other Income Core Pre-R&D Profit Core R&D Core Operating Profit 8,656 7,080 (85) (2,546) (2 546) 233 4,681 (1,692) (1 692) 2,990 CER growth 0% +1% -1% -12% 12% 0% +10% +31% +1% 81.8 1.0 29.5 29 5 2.7 54.1 19.5 19 5 34.5 +90bps 0bps +390bps 390 0bps +480bps -460bps 460 +20 bps % sales Delta vs PY CER

Financial Performance

Performance

128 128

Crestor
Q4 2011 Sales: $1,771m +11% CER Crestor US TRx +4%
1,800 1,600 1,400 1,200 1,000 800 600 400 200 0
Q4 10 US EST ROW Product Performance Q4 11 W EUR EM ROW
129 129

EM ROW $158m +8% EST ROW $465m +15% W. EUR $305m +5%

- Statin market flat - Share of total prescriptions in Dec 12.3% - Generic atorvastatin launched end November - Crestor TRx volume stable Western Europe were up 5 percent, largely on double-digit d bl di it growth i F th in France and S i d Spain Established Rest of World were up 15 percent, with Japan accounting for half of the increase E Emerging M k t were up 8 percent, where i Markets t h good growth in Emerging Europe and China was partially offset by generic erosion in Brazil Strong brand position for patients at elevated CV risk

US $843m +12%

Seroquel franchise
Q4 2011 Sales: $1,546m +15% CER Seroquel IR: $1,148m +12% Seroquel XR: $398m +27%
1,400 1,200 1,000 800 600 400 200 0
Q4 10 US EST ROW Product Performance Q4 11 W EUR EM ROW US $1,124m +20% EM ROW $81m -6% EST ROW $86m 19% W. W EUR $255m +3%

US Seroquel IR were $910 million, up 18% Market share for Seroquel franchise was a market leading 29.8% at end of Dec p p p y Total prescriptions for the US antipsychotic market were flat in the fourth quarter ROW q Seroquel franchise sales in the Rest of World were $422 million in the fourth quarter, a 3% increase Seroquel XR now 26% of global franchise revenue - US: 19% of franchise - ROW: 44% of franchise
130 130

Seroquel XR
Q4 2011 Sales: $398m +27% CER
400 350 300 250 200 150 100 50 0
Q4 10 US EST ROW Product Performance Q4 11 W EUR EM ROW US $214m +31% EM ROW $34m +37% EST ROW $23m +16% W. W EUR $127m +19%

US Seroquel XR were up 31 percent to $214 million. US Seroquel XR TRx +8% vs a flat market ROW Sales of Seroquel XR in ROW increased by 22%, accounting for 44% of franchise sales outside the US Emerging markets: Strong growth of Seroquel XR 37% Further launches completed in 2011 - MDD in Europe (Launched H1 in UK, Germany, Spain) - MDD and bipolar disorder in Emerging Markets - Xeroquel in France in BPD and schizophrenia in Nov
131 131

Symbicort
Q4 2011 Sales: $839m +13% CER US Symbicort TRx +9% 2% - Fixed combination market -2%
800 700 600 500 400 300 200 100 0
Q4 10 US EST ROW Product Performance Q4 11 W EUR EM ROW
132 132

EM ROW $115m +19% EST ROW $123m +26%

Symbicort TRx share increased to 20.3% in December 2011 New patient share 26% ROW Established ROW +26% - Fuelled by strong growth in Japan (up 56 percent)

W. EUR $ $359m +1%

US $242m +26%

Western Europe 1% - Data exclusivity in 10yr markets expired in Aug 2010 - Complex regulatory path for generics Emerging Markets +19% - China +40%

Nexium
Q4 2011 Sales: $1,067m, -13% CER
1,200 1,000 800 600 400 200 0
Q4 10 US EST ROW Product Performance Q4 11 EM ROW $176m +24% EST ROW $132m +5% W. EUR $145m -50%

US $614m -8%

W EUR EM ROW

US Retail volume -8 5% -8.5% - Generic penetration have significant impact on PPI market - decline in branded product prescription demand - low single digit decline in average selling prices was largely due to the impact of US healthcare reform C t effective promotion Cost ff ti ti - No direct detailing support - Effective use of new channels Digital Customer service representatives Telemarketing ROW Western Europe -50% - Generics are available all major European j p markets where France accounting for more than half of the decline Launched in Japan in September Emerging Markets +24% - China +36% 133
133

Iressa
Q4 2011 Sales: $149m +25% CER Strong g g growth in Western Europe and p Emerging Markets each accounting for about half of the sales increase Emerging Markets +38% - Including a 41% increase in China - 1st line EGFR M+ approvals
EST ROW $60m +2%

140 120 100 80 60 40 20 0

Q4 10 US EST ROW Product Performance Q4 11 W. W EUR $34m +70% US* $0m -100% EM ROW $55m +38%

Established ROW - 1st line EGFR M+ approval received in Japan Q4

W EUR EM ROW
134 134

*NDA withdrawn in the US Jan 2011

ONGLYZA Franchise
Q4 2011 Global Alliance Revenue: $ 71m + 122% CER
80 70 60 50 40 30 20 10 0
Q4 10 US EST ROW Product Performance Q411 W EUR EM ROW
135 135

EM ROW $5m +150% EST ROW $3m +200% W. EUR $10m +100%

US TRx growth of 1ppt in Q4 Franchise share reached 16.5% at end of Dec Kombiglyze XR success has lifted Onglyza franchise share of new patients to ~25% in the DPP4 class EU Komboglyze received marketing authorisation in EU in Q4 Est ROW / EM Launched in China Q4 2011 as the first DPP4 inhibitor Further approvals and launches expected during 2012

US $53m +121%

Investor Relations esto e at o s Contacts

IR Contacts

Investor Relations Contacts

Investor Enquiries London
James Ward-Lilley Karl Hrd james.ward-lilley@astrazeneca.com karl.j.hard@astrazeneca.com mob: +44 7789 654364 +44 207 604 8122 +44 207 604 8123 +44 207 604 8124

Nicklas Westerholm nicklas.westerholm@astrazeneca.com mob: +44 7585 404950

Investor Enquiries US
Ed Seage Jrgen Winroth g edward.seage@astrazeneca.com mob: +1 302 373 1361 j g jorgen.winroth@astrazeneca.com @ mob: +1 917 612 4043 +1 302 886 4065 +1 212 579 0506

IR Contacts

137 137

Cautionary Statement Regarding Forward-Looking Statements F d L ki St t t

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995 A t 1995, we are providing the following cautionary statement: This presentation contains certain f idi th f ll i ti t t t Thi t ti t i t i forward-looking d l ki statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those p y predicted. The forward-looking statements reflect knowledge and information g g available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include among other things: the loss or expiration of patents marketing exclusivity or trade marks control include, patents, marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability l i li bilit claims; the i th impact of any f il t f failure b thi d parties t supply materials or services; th risk of f il by third ti to l t i l i the i k f failure t to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in g g g g emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. Nothing in this presentation should be construed as a profit forecast.

138 138

Appendices ppe d ces

Appendices

Industry R&D spend growth

30%

25%

20%

15%

10%

5%

0%

-5% 5%

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

Market Growth yoy

Appendices

Source: EvaluatePharma July 2011

140

Healthcare MNC - Headcount Trend

1,000,000

950,000

900,000

Healthcare MNC - Headcount Trend 850,000

800,000

750,000 2006 2007 2008 2009 2010

Appendices

Source: EvaluatePharma Feb 2011 & Annual reports

141